Bora has announced the appointment of Samuel Ricchezza as President of North America Operations.
Bringing over 25 years’ CDMO experience to the team, Ricchezza is the former president for WellSpring Pharma Services and has held several senior roles at some of the industry’s most prominent contract service companies such as Patheon and AAIPharma (Alcami).
Bobby Sheng, CEO at Bora Pharmaceuticals commented: “We are delighted to have Sam as part of our growing team in the U.S. He adds invaluable experience and knowledge that will be essential to the success of our two-year expansion plans within the region.
“We have an ambitious growth strategy, and I can’t think of a better fit than Sam to propel this forward for our team.
“As our customers outsource more of their most challenging oral solid dose (OSD) requirements, Sam is also ideally placed to offer the on-hand senior support to help navigate these challenges.”
A new role for the publicly listed company, the appointment follows the recent opening of Bora’s corporate development office on the U.S. East Coast.
Ricchezza added: “I was attracted to Bora because of its ability to not only offer custom solutions for complex oral solid dose products but to also facilitate a worldwide business strategy for its customers given its expertise in multiple markets.
“Bora’s activity within North America is really exciting, and having supported the sale of WellSpring Pharma Services, I am thrilled to have the opportunity to sit on the other side of the table and advance Bora’s growth strategy in the region.”
Across its two sites in Taiwan, Bora offers a broad range of technologies to its global customer-base from development to large-scale manufacturing, packaging, distribution, tech transfer, stability studies, and product life cycle management.
Bora is one of the largest CDMOs in Asia and has strong financial foundations in place thanks, in-part, to core shareholders including, UMC and Taishin Financial Holdings, one of the largest banks in Taiwan.